Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6016 AL 6030

The impact of alcohol on Alzheimer's disease: a systematic review

Piazza-Gardner AK, Gaffud TJ, Barry AE.

Aging Ment Health. 2013;17(2):133-46. doi: 10.1080/13607863.2012.742488. Epub 2012 Nov 21.

Phosphodiesterases as therapeutic targets for Alzheimer's disease

García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R.

ACS Chem Neurosci. 2012 Nov 21;3(11):832-44. doi: 10.1021/cn3000907. Epub 2012 Oct 1.

Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

Smith B, Medda F, Gokhale V, Dunckley T, Hulme C.

ACS Chem Neurosci. 2012 Nov 21;3(11):857-72. doi: 10.1021/cn300094k. Epub 2012 Aug 28.

Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease

Trzepacz PT, Cummings J, Konechnik T, Forrester TD, Chang C, Dennehy EB, Willis BA, Shuler C, Tabas LB, Lyketsos C.

Int Psychogeriatr. 2013 May;25(5):707-19. doi: 10.1017/S1041610212002141. Epub 2012 Dec 21.

Auditory cortical function during verbal episodic memory encoding in Alzheimer's disease

Dhanjal NS, Warren JE, Patel MC, Wise RJ.

Ann Neurol. 2013 Feb;73(2):294-302. doi: 10.1002/ana.23789. Epub 2012 Dec 31.

Alzheimer's dementia: a brief review

Bassil N, Mollaei C.

J Med Liban. 2012 Oct-Dec;60(4):192-9.

Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics

Bakulski KM, Rozek LS, Dolinoy DC, Paulson HL, Hu H.

Curr Alzheimer Res. 2012 Jun;9(5):563-73. doi: 10.2174/156720512800617991.

[Review in geriatric medicine 2011]

Rochat S, Doser N, Eyer S, Jabri A, Rubli E, Büla C.

Rev Med Suisse. 2012 Jan 11;8(323):23-7.

Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease

Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS.

J Neural Transm (Vienna). 2012 Jul;119(7):843-50. doi: 10.1007/s00702-012-0772-4. Epub 2012 Feb 22.

[Achetylcholinesterase (AChE) inhibition and serum lipokines in Alzheimer's disease: friend or foe?]

Kovacs J, Pakaski M, Juhasz A, Feher A, Drotos G, Fazekas CO, Horvath TL, Janka Z, Kalman J.

Neuropsychopharmacol Hung. 2012 Mar;14(1):19-27.

Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures

Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P; Alzheimer’s Disease Cooperative Study.

Arch Neurol. 2012 Jul;69(7):836-41. doi: 10.1001/archneurol.2012.85.

Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients

Albani D, Martinelli Boneschi F, Biella G, Giacalone G, Lupoli S, Clerici F, Benussi L, Ghidoni R, Galimberti D, Squitti R, Mariani S, Confaloni A, Bruno G, Mariani C, Scarpini E, Binetti G, Magnani G, Franceschi M, Forloni G.

J Alzheimers Dis. 2012;30(4):745-9. doi: 10.3233/JAD-2012-112123.

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E; AAB-001 201/202 Investigators.

Arch Neurol. 2012 Aug;69(8):1002-10. doi: 10.1001/archneurol.2012.90.

Recruitment methods for United States Alzheimer disease prevention trials

Schneider LS.

J Nutr Health Aging. 2012 Apr;16(4):331-5. doi: 10.1007/s12603-012-0011-6.

Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease

Portelius E, Zetterberg H, Dean RA, Marcil A, Bourgeois P, Nutu M, Andreasson U, Siemers E, Mawuenyega KG, Sigurdson WC, May PC, Paul SM, Holtzman DM, Blennow K, Bateman RJ.

J Alzheimers Dis. 2012;31(2):335-41. doi: 10.3233/JAD-2012-120508.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias